| |
| | Durable remissions with fludarabine followed by Tositumomab and Iodine I 131 tositumomab (BEXXAR® therapeutic regimen) for patients with previously untreated follicular non-Hodgkin’s lymphoma. |
 | | Tositumomab and Iodine I 131 tositumomab therapy has been evaluated as single-agent therapy in addition to combination chemotherapy in the treatment of follicular lymphoma, both of which have led to impressive results in treatment of this disease. |
 | | The most common non-hematologic toxicities associated with tositumomab and Iodine I 131 tositumomab treatment were asthenia (43%), cough (29%), fever (29%), nausea (26%), and somnolence (23%). |
 | | [2],[3],[4]Tositumomab and Iodine I 131 tositumomab is comprised of the monoclonal antibody tositumomab, which is directed against the CD20 antigen, plus a radio-labeled tositumomab, which has been linked to radioactive Iodine-131. |
| professional.cancerconsultants.com /jc_issue1_nhl.aspx?id=32613 (1334 words) |
|